Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
Bayer
Pfizer
M.D. Anderson Cancer Center
Ono Pharmaceutical Co. Ltd
University College, London
Dana-Farber Cancer Institute
Daehwa Pharmaceutical Co., Ltd.